Global Ivosidenib
Market Report
2024
The Global Ivosidenib market size is USD 18.5 million in 2024 and will expand at a compound annual growth rate (CAGR) of 4.20% from 2024 to 2031.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Ivosidenib Market Report 2024.
According to Cognitive Market Research, The Global Ivosidenib market size is USD 18.5 million in 2024 and will expand at a compound annual growth rate (CAGR) of 4.20% from 2024 to 2031.
Base Year | 2023 |
Historical Data Time Period | 2019-2023 |
Forecast Period | 2024-2031 |
Global Ivosidenib Market Sales Revenue 2024 | $ 18.5 Million |
Global Ivosidenib Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 4.2% |
Middle East and Africa Ivosidenib Market Sales Revenue 2024 | $ 0.37 Million |
Middle East and Africa Ivosidenib Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 3.9% |
Asia Pacific Ivosidenib Market Sales Revenue 2024 | $ 4.26 Million |
Asia Pacific Ivosidenib Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 6.2% |
South America Ivosidenib Market Sales Revenue 2024 | $ 0.93 Million |
South America Ivosidenib Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 3.6% |
North America Ivosidenib Market Sales Revenue 2024 | $ 7.4 Million |
North America Ivosidenib Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 2.4% |
Europe Ivosidenib Market Sales Revenue 2024 | $ 5.55 Million |
Market Split by Patient Type |
|
Market Split by End-User |
|
Market Split by Distribution Channel |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Ivosidenib industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Ivosidenib Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Ivosidenib is an oral inhibitor of isocitrate dehydrogenase 1 (IDH1), a mutant enzyme in some malignancies, most notably acute myeloid leukemia (AML). It is marketed under the brand name Tibsovo. Ivosidenib was approved by the FDA in 2018 to treat individuals with an IDH1 mutation who have relapsed or are refractory to AML. Ivosidenib blocks the mutant enzyme, which stops uncontrollably large cell growth. With a focused therapy approach available for a particular genetic subset of AML patients, its approval represented a significant leap in precision medicine. Ivosidenib is a promising treatment for cancer that highlights the increasing significance of molecularly focused medicines in cancer care, especially when it comes to targeting specific genetic abnormalities that cause cancer.
Ivosidenib demand is mostly driven by the rising incidence of AML, or acute myeloid leukemia, which has a mutation in the FLT3 gene. Approximately 25–30% of all AML cases globally have FLT3 mutations. Ivosidenib targets a particular genetic subgroup and is effective in FLT3-mutated AML patients. It was created as a targeted therapy for patients with an IDH1 mutation. The rising rate of FLT3 mutation detection is attributed to several factors, including increased awareness, more diagnostic capabilities, and a greater understanding of genetic markers. Ivosidenib's ability to offer a tailored therapeutic solution for this genetic mutation makes it a desirable and sought-after therapy option in AML, particularly as precision medicine gains traction in cancer care.
The development of Ivosidenib has significantly improved the state of care for Acute Myeloid Leukemia (AML) with a FLT3 mutation. For individuals with AML who have an FLT3 mutation, there were few and often poorly performing choices before the discovery of Ivosidenib. A vital treatment gap has been closed with the launch of ivosidenib, a tailored medication created especially for AML patients with an IDH1 mutation. Because of its increased effectiveness, it provides a more advantageous course of treatment and addresses the particular genetic traits of FLT3 mutations. An important advancement in treating FLT3-mutated AML patients is ivosidenib's ability to provide a more focused and potent therapeutic approach. This improves the prognosis and quality of life for these patients.
Ivosidenib's high cost is a major issue that could be prohibitive for people and healthcare systems. For certain individuals, the expense of such an expensive prescription may make it less accessible and affordable. Ivosidenib's broad availability may also be impacted by budgetary and reimbursement issues that healthcare systems may encounter. Ensuring wider access to this targeted treatment for FLT3-mutated acute myeloid leukemia requires finding a balance between the therapeutic advantages of Ivosidenib and the financial concerns of patients and healthcare systems. Implementing cost-effective solutions and reimbursement support is crucial in mitigating the economic obstacles of Ivosidenib treatment.
The COVID-19 pandemic caused significant disruptions to the Ivosidenib market, mainly impacting patient access to clinical trials and healthcare services. Ivosidenib demand was impacted by the pandemic's effect on delayed diagnosis and treatment commencement for specific illnesses. Enrollments in clinical trials were impacted as well, which slowed down research. Nonetheless, the durability of the Ivosidenib market is anticipated to be bolstered by the significance of continuing cancer treatment and the gradual recovery of healthcare facilities following the pandemic. Ivosidenib is positioned as a critical treatment option for specific genetic abnormalities in disorders like acute myeloid leukemia since precision medicine and tailored medicines are still being prioritized.
We have various report editions of Ivosidenib Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Key players deploy strategic initiatives such as product innovations, partnerships, and mergers. Companies prioritize R&D to introduce cutting-edge reagents, ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.
Top Companies Market Share in Ivosidenib Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. Growing awareness and diagnosis of FLT3-mutated Acute Myeloid Leukemia (AML) are driving growth in the ivosidenib market in North America. Approximately 25–30% of AML cases have FLT3 mutations. Hence, ivosidenib's role as a targeted medication targets a sizable genetic population. The growing need for ivosidenib in North America is partly attributed to the region's focus on precision medicine and better treatment alternatives.
The Europe region is witnessing an increase in the sales of reagents. As more people in the region realize how important Ivosidenib is for treating FLT3-mutated Acute Myeloid Leukemia (AML), the market for the drug is expanding in Europe. The demand for Ivosidenib is driven by the growing recognition and diagnosis of FLT3 mutations, which account for many AML cases. Ivosidenib's market in Europe is growing due to the use of precision medicine and the accessibility of targeted medicines.
The current report Scope analyzes Ivosidenib Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
According to Cognitive Market Research, the global Ivosidenib market size was estimated at USD 18.5Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 0.37 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.9% from 2024 to 2031. The Middle East and Africa Ivosidenib market is starting to take off as a result of the region's growing recognition of the drug's importance in treating FLT3-mutated Acute Myeloid Leukemia (AML). A significant percentage of AML cases have FLT3 mutations, which has led to an increase in the demand for Ivosidenib. Prescriptions for sets of 60 or 30 tablets indicate that healthcare professionals in the Middle East and Africa, including hospitals and pharmacies, are gradually implementing this targeted medication. The progressive use of ivosidenib highlights the area's changing precision medicine strategy, providing customized treatment choices for AML patients with unique genetic traits and keeping pace with worldwide advances in oncology care.
According to Cognitive Market Research, the global Ivosidenib market size was estimated at USD 18.5Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 4.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. Asia Pacific's market for isoniazid is expanding significantly as more people in the area become aware of the medication's effectiveness in treating FLT3-mutated acute myeloid leukemia (AML). Ivosidenib demand is rising in Asia Pacific as a result of the discovery that FLT3 mutations are present in a sizable fraction of AML cases. Prescriptions for particular amounts, such as 60 or 30 pills, indicate that healthcare providers, such as hospitals and pharmacies, are actively promoting the market's growth. This highlights the growing significance of Ivosidenib in delivering tailored and efficient treatment in the context of the local healthcare system. The expansion of the market in Asia Pacific highlights a favorable trend toward customized treatments and precision medicine, which cater to the distinct genetic traits of AML patients in this region.
According to Cognitive Market Research, the global Ivosidenib market size was estimated at USD 18.5Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 0.93 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.6% from 2024 to 2031. Latin America's market for isoniazid is expanding as a result of the region's growing understanding of the drug's importance in treating FLT3-mutated acute myeloid leukemia (AML). A significant portion of AML cases have FLT3 mutations, which has led to an increase in the demand for Ivosidenib. Hospitals and pharmacies in Latin America are enthusiastically implementing this targeted therapy, as seen by prescriptions written for sets of 60 or 30 tablets. This highlights the increasing significance of Ivosidenib in delivering accurate and efficient treatment in the healthcare system of Latin America. The market's growth in Latin America is indicative of a trend in the right direction—the advancement of precision medicine and the provision of specialized treatment choices for patients with AML in this area.
According to Cognitive Market Research, the global Ivosidenib market size was estimated at USD 18.5Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD 7.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.4% from 2024 to 2031. North America's market for ivosidenib is expanding due to the region's focus on precision medicine and better treatment choices for Acute Myeloid Leukemia (AML), with a specific focus on FLT3-mutated cases. About 25–30% of AML cases include FLT3 mutations, which is what is fueling the demand for Ivosidenib. Due to the healthcare industry's recognition of Ivosidenib's effectiveness, hospitals and pharmacies, among others, have a significant impact on its expansion. The drug's growing popularity and significance in offering patients within this particular genetic subtype of AML focused and efficient treatment is highlighted by the prescription of precise quantities, such 60 or 30 pills. The market's growth is indicative of North America's dedication to improving oncology care via targeted therapeutics and precision medicine.
According to Cognitive Market Research, with a market value of USD 18.5 million in 2024, and projected to expand at a compound annual growth rate (CAGR) of 2.7% from 2024 to 2031. Europe accounted for a share of over 30% of the global Ivosidenib market size of USD 5.55 million. Europe's market for isoniazid is expanding significantly as a result of the region realizing how important this drug is for treating AML (acute myeloid leukemia) with FLT3 mutations. A significant proportion of AML cases have FLT3 mutations, which is one factor driving up the need for Ivosidenib. This targeted therapy is being actively adopted by European pharmacies and hospitals, as seen by prescriptions written for sets of pills, such as thirty or sixty. This emphasizes the usefulness and applicability of isosidenib in the European healthcare system, which is consistent with the continent's dedication to precision medicine and better treatment alternatives for patients with AML. The market's growth in Europe is indicative of a trend in the right direction—that is, the development of tailored therapies for certain genetic subgroups within the AML population.
Global Ivosidenib Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Ivosidenib Industry growth. Ivosidenib market has been segmented with the help of its Patient Type, End-User Distribution Channel, and others. Ivosidenib market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
According to Cognitive Market Research, adults hold a prominent market share. Ivosidenib's effectiveness in treating relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation is fueling the market's notable increase in the adult segment. Because adult patients with AML are the majority affected, there is a growing need for tailored treatments like Ivosidenib. Its ability to achieve remission and extend longevity in this patient population drives the rise of its market.
Pediatric is the fastest-growing category over the forecast period. Due to its potential efficacy in treating children patients with relapsed or refractory acute myeloid leukemia (AML) having an isocitrate dehydrogenase-1 (IDH1) mutation, the pediatric segment is emerging as a prominent driver of growth in the Ivosidenib market. Due to its capacity to induce remission and enhance survival rates in this particular patient population, ivosidenib is becoming more and more popular as a treatment for juvenile acute myeloid leukemia.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Ivosidenib Industry. Request a Free Sample PDF!
According to Cognitive Market Research, Clinics held the major market share over the forecast period. The market for isosidenib in hospitals is expanding as medical professionals become more aware of its effectiveness in treating acute myeloid leukemia (AML) with FLT3 mutations. Because FLT3 mutations represent a sizable portion of AML cases, hospitals are essential to the Ivosidenib administration process, which fuels the market's growth. The market for Ivosidenib is driven by the emphasis on precision medicine and enhanced therapeutic alternatives in hospital settings.
Homecare is the fastest-growing category over the forecast period. The expanding market for Ivosidenib, since they are essential in providing this targeted treatment for Acute Myeloid Leukemia (AML) with FLT3 mutations. Because pharmacies are important access sources for patients, the growing demand for Ivosidenib is supported by their provision and facilitation of its distribution. The availability of targeted treatments and the focus on precision medicine are further factors propelling the expansion of pharmacy environments.
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Ivosidenib market report 2024 Edition by contacting our team.
According to Cognitive Market Research, Hospital Pharmacies hold a prominent market share. Hospital pharmacies are a major source of ivosidenib for patients with relapsed or refractory acute myeloid leukemia (AML) who carry an isocitrate dehydrogenase-1 (IDH1) mutation. Hence, the market for this drug is expanding. Ivosidenib's market expansion in meeting unmet medical needs is facilitated by hospital pharmacies, which guarantee prompt availability of the medication and enable its administration as part of AML treatment protocols.
Retail Pharmacies are the fastest-growing category over the forecast period. Retail pharmacies are making Ivosidenib more accessible to patients with relapsed or refractory acute myeloid leukemia (AML) who have an isocitrate dehydrogenase-1 (IDH1) mutation, which is helping to drive the market for Ivosidenib. Retail pharmacies facilitate the expansion of the market for treating AML in community settings by stocking and dispensing Ivosidenib, a targeted medication which improves patient adherence and compliance.
Senior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
I am a dedicated and detail-oriented research analyst, committed to unraveling the stories hidden within data. With a solid foundation in market research & analysis, I thrive in the dynamic realm of research, where every dataset presents an opportunity for discovery. My passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.
I am committed to continuous professional development, regularly participating in workshops, attending conferences, and staying attuned to emerging trends in research methodologies to maintain the highest standards in my work. I played a vital role in conducting market research and competitive analysis. I have a proven track record of synthesizing diverse datasets, employing statistical models, and presenting comprehensive insights. My collaborative approach with cross-functional teams facilitated effective communication of findings, fostering a culture of data-driven decision-making within the organization.
Disclaimer:
Patient Type | Adult, Pediatric |
End-User | Clinics, Homecare, Ambulatory Surgical Centers |
Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
List of Competitors | Agios Pharmaceuticals |
This chapter will help you gain GLOBAL Market Analysis of Ivosidenib. Further deep in this chapter, you will be able to review Global Ivosidenib Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
Chapter 2 North America Market Analysis
Purchase Add-Ons to Customize the Report Edition and get further granular data level data about the North America market. Add-On Cost: Request before placing the order, Respective Pricing will be informed after sending the inquiry
Qualitative Analysis for the North America Market: North America Ivosidenib Market Trends North America Ivosidenib Technological Road Map North America Ivosidenib Market Drivers North America Ivosidenib Market Restraints North America Ivosidenib Market Opportunity Market Attractiveness Analysis COVID – 19 Impact Analysis PESTEL Analysis Porter’s Five Forces Analysis Product Life Cycle Industrial Chain Analysis
You can purchase only the Executive Summary North America Market (2019 vs 2024 vs 2031)
Chapter 3 Europe Market Analysis
You can purchase only the Executive Summary Europe Market (2019 vs 2024 vs 2031)
Chapter 4 Asia-Pacific Market Analysis
You can purchase only the Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
Chapter 5 South America Market Analysis
You can purchase only the Executive Summary South America Market (2019 vs 2024 vs 2031)
Chapter 6 Middle East and Africa Market Analysis
You can purchase only the Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Patient Type Analysis 2019 -2031, will provide market size split by Patient Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Patient Type Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by End-User Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Distribution Channel Analysis 2019 -2031
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Ivosidenib market
Chapter 13 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Why Adult have a significant impact on Ivosidenib market? |
What are the key factors affecting the Adult and Pediatric of Ivosidenib Market? |
What is the CAGR/Growth Rate of Clinics during the forecast period? |
By type, which segment accounted for largest share of the global Ivosidenib Market? |
Which region is expected to dominate the global Ivosidenib Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|
Published Report Editions
are Just a Tip of an Iceberg
Access the Complete Database of
Ivosidenib Market
Request Sample